Clinical trials: Stereotactic Body Radiation Therapy
Colorectal Cancer
Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
The purpose of this study is to determine the effects of CyberKnife stereotactic body radiotherapy in combination with irinotecan chemotherapy in patients with colon or rectal cancer that has spread to the liver.
- Trial name
- NCT01847495
- Testing
- Irinotecan, CyberKnife
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options…
- Conditions
- Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Cancer
- Trial name
- BOSS (NCT06055881)
- Testing
- Biospecimen Collection, Surveys, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Unspecified Adult Solid Tumor
Stereotactic Radiation Therapy in Treating Patients With Liver Metastases
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00938457
- Testing
- stereotactic radiation therapy, implanted fiducial-based imaging, cone-beam computed tomography
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
This phase II trial studies how well combination chemotherapy with or without oregovomab followed by stereotactic body radiation therapy (SBRT) and nelfinavir mesylate works in treating patients with pancreatic cancer that has…
- Conditions
- Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer
- Trial name
- NCT01959672
- Testing
- 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Hepatocellular Carcinoma
A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma
Notable-HCC is a phase Ib study of neoadjuvant stereotactic body radiotherapy (SBRT) plus Programmed cell death-1 (PD-1, Tislelizumab, BeiGene) prior to hepatic resection in patients with resectable HCC.
- Trial name
- Notable-HCC (NCT05185531)
- Testing
- PD-1 plus stereotactic body radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong Cancer Hospital and Institute
Lung Carcinoma, Malignant Respiratory Tract Neoplasm
Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer
This pilot phase I/II trial studies how well a continuous positive airway pressure device or deep inspiration breath hold works in reducing tumor movement in patients undergoing stereotactic body radiation therapy (SBRT) for lung…
- Conditions
- Lung Carcinoma, Malignant Respiratory Tract Neoplasm, Metastatic Malignant Neoplasm in the Lung
- Trial name
- NCT03422302
- Testing
- Biphasic Positive Airway Pressure, Computed Tomography, Continuous Positive Airway Pressure
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Merkel Cell Carcinoma
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with MCC who have progressed on or after anti-PD-L1 therapy.
- Trial name
- NCT03167164
- Testing
- Avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.
Nasopharyngeal Carcinoma
Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma
In this exploratory clinical trial, patients with newly diagnosed distant metastatic nasopharyngeal carcinoma were treated with gemcitabine+ cisplatin+PD-1 inhibitor regimen followed by whole-target radiotherapy (IMRT for local…
- Trial name
- NCT05431764
- Testing
- Camrelizumab, gemcitabin, cisplatin, Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sun Yat-sen University
Ovarian Cancer
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with epithelial ovarian cancer who have progressed on or after SoC therapy.
- Trial name
- NCT03197584
- Testing
- Avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.
Pancreatic Cancer
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
Pancreatic cancer is a cancer with a poor prognosis and a high mortality rate. The prognosis of surgically resectable pancreatic cancer is better than that of unresectable pancreatic cancer.
- Trial name
- NCT05679583
- Testing
- Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Yonsei University
Colorectal Cancer, Retroperitoneal Lymph Node Metastasis
CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRC
The study aims to compare the effects of chemoradiation versus radical surgery in treating retro-peritoneal or para-aortic lymph node metastasis in colorectal cancer.
- Conditions
- Colorectal Cancer, Retroperitoneal Lymph Node Metastasis, Para-aortic Lymph Node Metastasis
- Trial name
- NCT03725254
- Testing
- lymphadenectomy, chemoradiotherapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Fudan University
Malignancy, Breast Cancer Metastatic
The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease
Systemic therapy is the main treatment for patients with metastatic cancers. Oligo-progression has become a recognized entity for metastatic cancer and it is thought that a subset of cancer cells may develop heterogeneity and…
- Conditions
- Malignancy, Breast Cancer Metastatic, Genito-urinary
- Trial name
- RADIANT (NCT04122469)
- Testing
- Stereotactic Body Radiotherapy
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- University Health Network, Toronto
Metastatic Cancer
Single-isocenter SBRT vs. Multiple-isocenter SBRT for Multiple Extracranial Metastases
The goal of this randomized non-inferiority clinical trial is to investigate whether single-isocenter SBRT using one treatment plan is similarly effective as multiple-isocenter SBRT using multiple treatment plans for multiple…
- Trial name
- NCT06230666
- Testing
- SBRT
- Where
- Switzerland
- Volunteers
- 62 people
- Sponsor
- Matthias Guckenberger
Oligometastatic Prostate Cancer
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission…
- Trial name
- POPSTAR II (NCT05560659)
- Testing
- 177Lu-PSMA
- Where
- 3 sites in Australia, Israel
- Volunteers
- 92 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Non-small Cell Lung Cancer
Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
Stereotactic body radiation therapy (SBRT) is a special form of treatment which pinpoints high doses of radiation directly to cancer.
- Trial name
- NCT01525446
- Testing
- SBRT with proton beam radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
HR-positive,HER2-negative Breast Cancer
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
This study is the first to explore the clinical study of neoadjuvant radiotherapy followed by chemotherapy combined with terriplizumab in breast cancer.
- Trial name
- NCT06705127
- Testing
- TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Endometrial Cancer, Radiotherapy, Adjuvant
MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer
Rationale: External beam radiotherapy (EBRT) is an important cornerstone in treatment to reduce locoregional relapse in high(-intermediate) risk endometrial cancer (EC) patients.
- Trial name
- MASTEC (NCT07514325)
- Testing
- MR-guided adaptive radiotherapy (MGART) with reduced PTV margins, including 5 times 6Gy to the vaginal vault and pelvic nodal areas, 2 times a week
- Volunteers
- 61 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.
- Trial name
- NCT06391034
- Testing
- hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT)
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Robert Bok, MD, PhD
Prostate Cancer
Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
- Trial name
- fBTsRT (NCT04100174)
- Testing
- focal brachytherapy boost to SBRT
- Where
- 2 sites in Canada
- Volunteers
- 150 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
This phase I/II trial studies the side effects and how well nivolumab and ipilimumab works when given together with stereotactic body radiation therapy (SBRT) in treating patients with salivary gland cancers.
- Conditions
- Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung, Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8
- Trial name
- NCT03749460
- Testing
- Nivolumab, Ipilimumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.